MFSD2A Allosteric Modulation for Reversible BBB Permeability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing technologies lack selective transport inhibitors to reversibly permeabilize the blood-brain barrier (BBB) for delivering therapeutic molecules into the brain, and the mechanism of MFSD2A-mediated lipid transport across the BBB remains incompletely understood.
Innovation Solution
Identification of allosteric modulators, specifically SYNC2 polypeptide fragments, that inhibit MFSD2A lipid transport and enhance transcytosis, facilitating the passage of small compounds, macromolecules, and nanomaterials across the BBB through receptor-mediated mechanisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If MFSD2A transport function is maintained for normal BBB function, then essential lipid uptake is ensured, but BBB permeability to therapeutic molecules remains restricted
Solution Approach 1:
The patent uses soluble SYNC2 fragments as intermediary molecules that bind to MFSD2A and act as allosteric modulators, changing the transporter's conformation to increase BBB permeability while maintaining essential lipid uptake function
Solution Approach 2:
The patent changes the functional state of MFSD2A from its normal transport mode to an allosterically modulated state with increased permeability, allowing therapeutic molecules to pass through while maintaining essential functions
2Productivity
If BBB permeability is increased to deliver therapeutic molecules, then drug delivery is improved, but selective control over which molecules pass through is lost
Solution Approach 1:
The soluble SYNC2 fragment acts as a selective intermediary that specifically binds to MFSD2A and induces controlled permeability changes, ensuring that only molecules that can utilize the modified transport pathway benefit from increased permeability
Solution Approach 2:
The MFSD2A transporter itself provides the selective control mechanism by using its natural substrate binding site and allosteric modulation pathway to regulate which molecules can pass through the BBB
3Ease of operation
If allosteric modulators are developed to inhibit MFSD2A, then BBB permeability control is achieved, but the transport mechanism remains incompletely understood
Solution Approach 1:
The use of soluble SYNC2 fragments as allosteric modulators provides feedback information about MFSD2A conformational changes and transport mechanism, helping to elucidate how the transporter functions while simultaneously providing control over BBB permeability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The SYNC2 fragments provide a unique mechanism to increase BBB permeability, allowing for the delivery of therapeutic molecules, including antibodies, DNA, RNA, and nanomaterials, by enhancing transcytosis rates and receptor-mediated transport.
Implementation Method 1
Identification of allosteric modulators, specifically SYNC2 polypeptide fragments, that inhibit MFSD2A lipid transport
Implementation Method 2
MFSD2A transports esterified DHA in the form of lysophosphatidylcholine (LPC) in a Na+ dependent manner
Implementation Method 3
cell-cell fusion is achieved by a retroviral mechanism and mediated by binding of envelope glycoproteins of retroviral origin, known as syncytin (SYNC), to cellular receptors
Data Source
AI summary
The disclosure provides the structure of an MFSD2A-SYNC2 complex together with functional data that revealed important molecular aspects of MFSD2A transport cycle, receptor-mediated cell-cell fusion, and pharmacology and resulted in the identification of two novel allosteric modulators of MFSD2A, which are two soluble fragments of SYNC2, namely SYNC2su-co and SYNC2su-co-2, representing first-in-class molecules to inhibit MFSD2A LPCs uptake and increase transcytosis rate.